Advances in the pharmacological management of Huntingtons disease

Drugs

Volumn 70, Issue 5, 2010, Pages 561-571

  Frank, Samuel ^a   Jankovic, Joseph ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIOXIDANT; ARIPIPRAZOLE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; CANNABINOID; CHOLINESTERASE INHIBITOR; CLONAZEPAM; CLOZAPINE; CREATINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMATE RECEPTOR ANTAGONIST; HALOPERIDOL; ICOSAPENTAENOIC ACID ETHYL ESTER; IDEBENONE; LAMOTRIGINE; LEVODOPA; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RESERPINE; RILUZOLE; RISPERIDONE; TETRABENAZINE; UBIDECARENONE; UNINDEXED DRUG;

AGGRESSIVENESS; AGITATION; AKATHISIA; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; APATHY; BRAIN DEGENERATION; BRAIN DEPTH STIMULATION; CELL TRANSPLANTATION; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE COURSE; DNA DETERMINATION; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOCAL DYSTONIA; HUMAN; HUNTINGTON CHOREA; HYPERKINESIA; INSOMNIA; IRRITABILITY; MOOD DISORDER; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; OROMANDIBULAR DYSTONIA; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PATIENT EDUCATION; PREVALENCE; PSYCHOSIS; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; SMELLING; SOMNOLENCE; SUICIDE; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; VERBAL MEMORY; WALKING DIFFICULTY;

ANIMALS; ANTIPSYCHOTIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; HUNTINGTON DISEASE; NEUROPROTECTIVE AGENTS; TETRABENAZINE; TREATMENT OUTCOME;

EID: 77949988313     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11534430-000000000-00000     Document Type: Review

References (122)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72 (6): 971-983
2. Nucifora Jr FC, Sasaki M, Peters MF, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001; 291 (5512): 2423-2428
3. Subramaniam S, Sixt KM, Barrow R, et al. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009; 324 (5932): 1327-1330
4. Andrich J, Saft C, Ostholt N, et al. Complex movement behaviour and progression of Huntington's disease. Neurosci Lett 2007; 416 (3): 272-274
5. Frank S, Marshall F, Plumb S, et al. Functional decline due to chorea in Huntington's disease. Neurology 2004; 62 Suppl. 5: A204
6. Verhagen ML, Morris MJ, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002; 59 (5): 694-699
7. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 2003; 361 (9369): 1642-1644
8. Arrasate M, Mitra S, Schweitzer ES, et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004; 431 (7010): 805-810
9. Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000; 97 (3): 505-519
10. Albin RL, Reiner A, Anderson KD, et al. Preferential loss of striato-external pallidal projection neurons in pre-symptomatic Huntington's disease. Ann Neurol 1992; 31 (4): 425-430
11. Reiner A, Albin RL, Anderson KD, et al. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 1988; 85 (15): 5733-5737
12. Mitchell IJ, Cooper AJ, Griffiths MR. The selective vulnerability of striatopallidal neurons. Prog Neurobiol 1999; 59 (6): 691-719
13. Antonini A, Leenders KL, Spiegel R, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Hunting-ton's disease. Brain 1996; 119 (Pt 6): 2085-2095
14. Augood SJ, Faull RL, Emson PC. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol 1997; 42 (2): 215-221
15. Feigin A, Tang C, Ma Y, et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 2007; 130 (Pt 11): 2858-2867
16. Andrews TC, Weeks RA, Turjanski N, et al. Huntington's disease progression. PET and clinical observations. Brain 1999; 122 (Pt 12): 2353-2363
17. Weeks RA, Piccini P, Harding AE, et al. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol 1996; 40 (1): 49-54
18. Cha JH, Kosinski CM, Kerner JA, et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci USA 1998; 95 (11): 6480-6485
19. Perry TL, Hansen S, Kloster M. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain. N Engl J Med 1973; 288 (7): 337-342
20. Paulsen JS. Functional imaging in Huntington's disease. Exp Neurol 2009; 216 (2): 272-277
21. Gourfinkel-An I, Parain K, Hartmann A, et al. Changes in GAD67 mRNA expression evidenced by in situ hybridization in the brain of R6/2 transgenic mice. J Neuro-chem 2003; 86 (6): 1369-1378
22. Nicniocaill B, Haraldsson B, Hansson O, et al. Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. Eur J Neurosci 2001; 13 (1): 206-210
23. Harper PS. The epidemiology of Huntington's disease. Hum Genet 1992; 89 (4): 365-376
24. Morrison PJ, Johnston WP, Nevin NC. The epidemiology of Huntington's disease in Northern Ireland. J Med Genet 1995; 32 (7): 524-530
25. Peterlin B, Kobal J, Teran N, et al. Epidemiology of Huntington's disease in Slovenia. Acta Neurol Scand 2009; 119 (6): 371-375
26. Simpson SA, Johnston AW. The prevalence and patterns of care of Huntington's chorea in Grampian. Br J Psychiatry 1989; 155: 799-804
27. Penney Jr JB, Young AB, Shoulson I, et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 1990; 5 (2): 93-99
28. Ribai P, Nguyen K, Hahn-Barma V, et al. Psychiatric and cognitive difficulties as indicators of juvenile hun-tington disease onset in 29 patients. Arch Neurol 2007; 64 (6): 813-819
29. Biglan KM, Ross CA, Langbehn DR, et al., PREDICTHD Investigators of the Huntington Study Group. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord 2009 Sep 15; 24 (12): 1763-1772
30. Tabrizi SJ, Langbehn DR, Leavitt BR, et al., TRACK-HD investigators. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009 Sep; 8 (9): 791-801
31. Huntington Study Group PHAROS Investigators (Shoulson I, primary author). At risk for Huntington's disease: the PHAROS (Prospective Huntington at risk observational study) cohort enrolled. Arch Neurol 2006; 63: 991-998
32. Huntington Study Group. Cooperative Huntington's Observational Research Trial [ClinicalTrials.gov identifier NCT00313495]. US National Institutes of Health. Clinical Trials.gov [online]. Available from URL: http://www.clini caltrials.gov [Accessed 2010 Jan 26]
33. Solomon AC, Stout JC, Johnson SA, et al., Predict-HD investigators of the Huntington Study Group. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia 2007 Apr 9; 45 (8): 1767-1776
34. Johnson SA, Stout JC, Solomon AC, et al., Predict-HD Investigators of the Huntington Study Group. Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain 2007 Jul; 130 (Pt 7): 1732-1744
35. Paulsen JS, Langbehn DR, Stout JC, et al., Predict-HD Investigators and Coordinators of the Huntington Study Group. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008 Aug; 79 (8): 874-880
36. Duff K, Paulsen JS, Beglinger LJ, et al., Predict-HD Investigators of the Huntington Study Group. Psychiatric symptoms in Huntington's disease before diagnosis: the Predict-HD study. Biol Psychiatry 2007 Dec 15; 62 (12): 1341-1346
37. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11 (2): 136-142
38. The American College of Medical Genetics/American Society of Human Genetics Huntington Disease Genetic Testing Working Group. ACMG/ASHG statement. Laboratory guidelines for Huntington disease genetic testing. Am J Hum Genet 1998; 62 (5): 1243-1247
39. Andrich J, Arning L, Wieczorek S, et al. Huntington's disease as caused by 34 CAG repeats. Mov Disord 2008; 23 (6): 879-881
40. Kenney C, Powell S, Jankovic J. Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord 2007; 22 (1): 127-130
41. Snell RG, MacMillan JC, Cheadle JP, et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 1993; 4 (4): 393-397
42. Di ML, Squitieri F, Napolitano G, et al. Suicide risk in Huntington's disease. J Med Genet 1993; 30 (4): 293-295
43. Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics 2008; 5 (2): 181-197
44. Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord 2008; 23 (11): 1491-1504
45. Roze E, Saudou F, Caboche J. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr Opin Neurol 2008; 21 (4): 497-503
46. Imarisio S, Carmichael J, Korolchuk V, et al. Huntington's disease: from pathology and genetics to potential therapies. Biochem J 2008; 412: 191-209
47. Walker FO. Huntington's disease. Lancet 2007; 369 (9557): 218-228
48. Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol 2009; 8 (9): 844-856
49. Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006; 12 (21): 2701-2720
50. Nakamura K, Aminoff MJ. Huntington's disease: clinical characteristics, pathogenesis and therapies. Drugs Today (Barc) 2007; 43 (2): 97-116
51. Handley OJ, Naji JJ, Dunnett SB, et al. Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin Sci (Lond) 2006; 110 (1): 73-88
52. Bonelli RM, Hofmann P. A review of the treatment options for Huntington's disease. Expert Opin Pharmacother 2004; 5 (4): 767-776
53. Grimbergen YA, Roos RA. Therapeutic options for Huntington's disease. Curr Opin Investig Drugs 2003; 4 (1): 51-54
54. Bagchi SP. Differential interactions of phencyclidine with tetrabenazine and reserpine affecting intraneuronal dopamine. Biochem Pharmacol 1983; 32 (19): 2851-2856
55. Pettibone DJ, Pflueger AB, Totaro JA. Tetrabenazine-induced depletion of brain monoamines: mechanism by which desmethylimipramine protects cortical norepine-phrine. Eur J Pharmacol 1984; 102 (3-4): 431-436
56. Mehvar R, Jamali F. Concentration-effect relationships of tetrabenazine and dihydrotetrabenazine in the rat. J Pharm Sci 1987; 76 (6): 461-465
57. Thibaut F, Faucheux BA, Marquez J, et al. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine. Brain Res 1995; 692 (1-2): 233-243
58. Kenney C, Hunter C, Davidson A, et al. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord 2007; 22 (1): 10-13
59. Scherman D, Henry JP. Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding. Mol Pharmacol 1984; 25 (1): 113-122
60. Mehvar R, Jamali F, Watson MW, et al. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. Drug Metab Dispos 1987; 15 (2): 250-255
61. Roberts MS, Watson HM, McLean S, et al. Determination of therapeutic plasma concentrations of tetrabenazine and an active metabolite by high-performance liquid chro-matography. J Chromatogr 1981; 226 (1): 175-182
62. Roberts MS, McLean S, Millingen KS, et al. The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders. Eur J Clin Pharmacol 1986; 29 (6): 703-708
63. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006; 66 (3): 366-372
64. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48 (2): 358-362
65. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007; 22 (2): 193-197
66. Fasano A, Cadeddu F, Guidubaldi A, et al. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol 2008; 31 (6): 313-318
67. Huntington Study Group/Tetra-HD Investigators. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. BMC Neurol 2009 Dec 18; 9 62.
68. Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry 1984; 47 (8): 844-847
69. Deroover J, Baro F, Bourguignon RP, et al. Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Curr Med Res Opin 1984; 9 (5): 329-338
70. Leonard DP, Kidson MA, Brown JG, et al. A double blind trial of lithium carbonate and haloperidol in Huntington's chorea. Aust N Z J Psychiatry 1975; 9 (2): 115-118
71. Barr AN, Fischer JH, Koller WC, et al. Serum haloperidol concentration and choreiform movements in Hunting-ton's disease. Neurology 1988; 38 (1): 84-88
72. Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington's disease: an open label study. Clin Neuro-pharmacol 2002; 25 (5): 263-265
73. Bonelli RM, Niederwieser G, Tribl GG, et al. High-dose olanzapine in Huntington's disease. Int Clin Psycho-pharmacol 2002; 17 (2): 91-93
74. Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand 2002; 105 (6): 441-444
75. Squitieri F, Cannella M, Piorcellini A, et al. Short-term effects of olanzapine in Huntington disease. Neuro-psychiatry Neuropsychol Behav Neurol 2001; 14 (1): 69-72
76. Dipple HC. The use of olanzapine for movement disorder in Huntington's disease: a first case report. J Neurol Neurosurg Psychiatry 1999; 67 (1): 123-124
77. Cankurtaran ES, Ozalp E, Soygur H, et al. Clinical experience with risperidone and memantine in the treatment of Huntington's disease. J Natl Med Assoc 2006; 98 (8): 1353-1355
78. Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington's disease. Eur J Neurol 2002; 9 (2): 182-183
79. Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington's disease. Am J Geriatr Psychiatry 1998; 6 (4): 347-349
80. Parsa MA, Szigethy E, Voci JM, et al. Risperidone in treatment of choreoathetosis of Huntington's disease. J Clin Psychopharmacol 1997; 17 (2): 134-135
81. Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. Psychosomatics 2006; 47 (1): 70-72
82. Seitz DP, Millson RC. Quetiapine in the management of psychosis secondary to Huntington's disease: a case report. Can J Psychiatry 2004; 49 (6): 413
83. Bonelli RM, Niederwieser G. Quetiapine in Huntington's disease: a first case report. J Neurol 2002; 249 (8): 1114-1115
84. van Vugt JP, Siesling S, Vergeer M, et al. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997; 63 (1): 35-39
85. Ciammola A, Sassone J, Colciago C, et al. Aripiprazole in the treatment of Huntington's disease: a case series. Neuropsychiatr Dis Treat 2009; 5: 1-4
86. Brusa L, Orlacchio A, Moschella V, et al. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009; 24 (1): 126-129
87. Lin WC, Chou YH. Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease. Am J Psychiatry 2008; 165 (9): 1207-1208
88. Lucetti C, Gambaccini G, Bernardini S, et al. Amantadine in Huntington's disease: open-label video-blinded study. Neurol Sci 2002; 23 Suppl. 2: S83-4
89. Stewart JT. Adverse behavioral effects of amantadine therapy in Huntington's disease. South Med J 1987; 80 (10): 1324-1325
90. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 2003; 61 (11): 1551-1556
91. Landwehrmeyer GB, Dubois B, de Yebenes JG, et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007; 62 (3): 262-272
92. Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust 1976; 1 (8): 225-227
93. Frattola L, Albizzati MG, Alemani A, et al. Acute treatment of Huntington's chorea with lisuride. J Neurol Sci 1983; 59 (2): 247-253
94. Vitale C, Marconi S, Di ML, et al. Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: a double blind, randomized crossover trial. Mov Disord 2007; 22 (16): 2359-2364
95. Corsini GU, Onali P, Masala C, et al. Apomorphine hydrochloride-induced improvement in Huntington's chorea: stimulation of dopamine receptor. Arch Neurol 1978; 35 (1): 27-30
96. Low PA, Allsop JL, Halmagyi GM. Huntington's chorea: the rigid form (Westphal variant) treated with levodopa. Med J Aust 1974; 1 (11): 393-394
97. Low PA, Allsop JL. Huntington's chorea-the rigid form (Westphal variant) treated with l-DOPA: a case report. Proc Aust Assoc Neurol 1973; 10 (0): 45-46
98. Magnet MK, Bonelli RM, Kapfhammer HP. Amantadine in the akinetic-rigid variant of Huntington's disease. Ann Pharmacother 2004; 38 (7-8): 1194-1196
99. Bonelli RM, Niederwieser G, Diez J, et al. Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease. Clin Neuro-pharmacol 2002; 25 (1): 58-60
100. Tan EK, Jankovic J, Ondo W. Bruxism in Huntington's disease. Mov Disord 2000; 15 (1): 171-173
101. Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci 2004; 5 (5): 373-384
102. Hersch SM, Ferrante RJ. Translating therapies for Huntington's disease from genetic animal models to clinical trials. NeuroRx 2004; 1 (3): 298-306
103. Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006; 66 (2): 250-252
104. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001; 57 (3): 397-404
105. Curtis A, Rickards H. Nabilone could treat chorea and irritability in Huntington's disease. J Neuropsychiatry Clin Neurosci 2006; 18 (4): 553-554
106. Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991; 40 (3): 701-708
107. Muller-Vahl KR, Schneider U, Emrich HM. Nabilone increases choreatic movements in Huntington's disease. Mov Disord 1999; 14 (6): 1038-1040
108. Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev 2009; (3): CD006455
109. Massachusetts General Hospital. Creatine Safety and Tolerability in Premanifest HD [ClinicalTrials.gov identifier NCT00592995]. US National Institutes of Health. Clinical Trials.gov [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2010 Jan 26]
110. Hersch SM, Rosas HD. Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics 2008; 5 (2): 226-236
111. Tedroff J, Ekesbo A, Sonesson C, et al. Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease. Neurology 1999; 53 (7): 1605-1606
112. Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 2008; 65 (12): 1582-1589
113. Huntington Study Group. PHEND-HD: a safety, tolerability, and biomarker study of phenylbutyrate in symptomatic HD [abstract]. Neurotherapeutics 2008; 5 (2): 363
114. Huntington Study Group. A phase 2 trial of minocycline in Huntington's disease [abstract]. Mov Disord 2009; 24 Suppl. 1: S164
115. Yang L, Calingasan NY, Wille EJ, et al. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem 2009; 109 (5): 1427-1439
116. Pan T, Kondo S, Le W, et al. The role of autophagylysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008; 131 (Pt 8): 1969-1978
117. Mostert JP, Koch MW, Heerings M, et al. Therapeutic potential of fluoxetine in neurological disorders. CNS Neurosci Ther 2008; 14 (2): 153-164
118. US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL http://www.clinicaltrials.gov [Accessed 2010 Jan 26]
119. Kieburtz K, McDermott MP, Voss TS, et al. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol 2010; 67 (2): 154-160
120. Wang X, Zhu S, Pei Z, et al. Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease. J Neurosci 2008; 28 (38): 9473-9485
121. Graham RK, Deng Y, Slow EJ, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006; 125 (6): 1179-1191
122. Kaltenbach LS, Romero E, Becklin RR, et al. Huntingtin interacting proteins are genetic modifiers of neurodegen-eration. PLoS Genet 2007 May 11; 3 (5): e82